By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Life Technologies today announced a licensing agreement for Novici Biotech's technology for DNA-error correction as part of its continued expansion into the synthetic biology space.

Under the terms of the deal, Life Tech will integrate Novici's ErrAse DNA-error correction kit into its synthetic biology offerings and retain all rights to sublicense the technology. ErrAse will be available for research purposes through Novici until it is launched with the Life Tech name.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.